drugset

drugset / Trial / NCT04014023

Study to Evaluate the Efficacy and Safety of DWP16001 in Patients With Type 2 Diabetes Mellitus

NCT04014023 ↗

Phase 2 Unknown 196 enrolled Daewoong Pharmaceutical Co. LTD.

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the efficacy and safety of DWP16001 compared to placebo in the treatment of type 2 diabetes mellitus.

Timeline

Start: 2019-07-10
Primary completion: 2020-03
Completion: 2020-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Enavogliflozin	Small molecule	—	Oral

Indications